KT-621 for Asthma

(BREADTH Trial)

Recruiting at 1 trial location

Overseen By Kymera Medical Director

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Kymera Therapeutics, Inc.

Must be taking: Inhaled corticosteroids, Long-acting β2-agonists

Disqualifiers: Other pulmonary disease, Pregnancy, Smoking, others

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: 12 weeks

264 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma.

The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.

Are You a Good Fit for This Trial?

Adults aged 18-75 with a physician's diagnosis of asthma for at least one year, currently on a stable regimen of medium to high-dose inhaled corticosteroids and long-acting β2-agonists. Participants must have moderate to severe eosinophilic asthma, as indicated by specific breathing tests and blood eosinophil counts. They should have had an asthma exacerbation within the last year.

Inclusion Criteria

My blood test shows eosinophils are high enough.

I agree to follow the study's birth control requirements.

I have been diagnosed with asthma by a doctor for at least 1 year.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive KT-621 or placebo to evaluate efficacy and safety in treating uncontrolled moderate to severe eosinophilic asthma

12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• KT-621
• Placebo

Trial Overview

The trial is testing KT-621 against a placebo in adults with uncontrolled moderate to severe eosinophilic asthma. It aims to assess how well KT-621 works, its safety, tolerability, and behavior in the body over time compared to no active treatment.

How Is the Trial Designed?

Group I: Group 3: KT-621 Dose 3 Experimental Treatment 1 Intervention

Group II: Group 2: KT-621 Dose 2 Experimental Treatment 1 Intervention

Group III: Group 1: KT-621 Dose 1 Experimental Treatment 1 Intervention

Group IV: Group 4: Placebo Placebo Group 1 Intervention

Who Is Running the Clinical Trial?

Kymera Therapeutics, Inc.

Lead Sponsor

Trials

8

Recruited

850+